We envision a future where every patient has access to treatment. Through the CRD drug development model, we aim to increase the efficiency of developing treatments for neglected diseases, ensuring that patients have access to the hope of a healthier future.
Ultra-rare disease is a hidden epidemic.
people are diagnosed with a rare disease. The majority affected are children.
rare-diseases and counting. Most are life-threatening.
of all rare diseases currently have no treatment or cure.
In the U.S. and Canada alone, 37 million people have a rare disease.
Our model aims to streamline and de-risk the development of therapies for ultra-rare diseases.
CRD selects a disease and identifies academic research collaborators. We establish a research agreement to enable early stage development.
CRD and our partners prototype and develop a therapeutic proof of concept capable of fixing mutations in the cell line.
CRD and our partners test therapeutic candidates and move the lead candidate into clinical trials, submitting an IND application to the FDA.
Once the drug is approved by the FDA, it can ultimately be licensed and sold, opening up treatment paths for more patients.
CRD is a builder, streamlining a fragmented system.
CRD is a drug development engine, bringing together early stage research with CRD’s drug development expertise.
Partner With Us
Provide early stage drug design and development expertise
Provide treatments to neglected, ultra-rare disease patients
Provide information and support to families and community groups
Provide de-risked pipeline of new technologies
Your involvement helps shape our research and ensures our therapies meet real patient needs.
Cure Rare Disease, a non-profit organization (Tax ID number 82-2473513), is qualified as a tax-exempt organization under section 501(c)(3) of the IRS and has been designated as a “public charity” under section 170.
